REPL -
Replimune Group, Inc.
| Day |
1m |
10m |
60m |
PreMarket |
Market |
AfterHours |
Gap |
| 8.6 0.8 (9.36%) |
-0.01 (-0.11%) |
-0.02 (-0.16%) |
-0.01 (-0.05%) |
0.4 (4.65%) |
0.42 (4.73%) |
--- |
0.4 (4.65%) |
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.
Earnings & Ratios
- Basic EPS:
- -0.95
- Diluted EPS:
- -0.95
- Basic P/E:
- -9.9
- Diluted P/E:
- -9.9
- RSI(14) 1m:
- 65.22
- VWAP:
- 9.41
- RVol:
Events
| Period |
Kind |
Movement |
Occurred At |
Related News
Replimune Presents Late-Breaking Abstract and Additional Posters on RP1 at 40th Annual Meeting of the Society for the Immunotherapy of Cancer (SITC 2025)
Nov 07, 2025 21:45
Why Replimune Stock Was Soaring Today
Oct 20, 2025 20:10
Replimune Announces FDA Acceptance of BLA Resubmission of RP1 for the Treatment of Advanced Melanoma
Oct 20, 2025 11:00
Replimune Highlights Acral Melanoma Data for RP1 plus Nivolumab at the ESMO Congress 2025
Oct 19, 2025 12:00
REPL FINAL DEADLINE ALERT: Replimune (REPL) Shares Tank 45% After Company Says No Pathway Identified For Lead Drug RP1, Securities Class Action Pending - Hagens Berman
Sep 21, 2025 15:20
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Replimune
Sep 21, 2025 11:40
REPL DEADLINE TOMORROW: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Replimune Group, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – REPL
Sep 21, 2025 10:09
מחר המועד האחרון לתביעה נגד REPL: רוזן, יועץ למשקיעים מיומן, מעודד את משקיעי Replimune Group, Inc. שצברו הפסדים של יותר מ- 100 אלף דולר להבטיח ייעוץ לפני המועד האחרון החשוב בתביעה ייצוגית בניירות ערך שהוגשה ראשונה על ידי המשרד – REPL
Sep 21, 2025 10:09
REPLIMUNE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Replimune Group, Inc. and Encourages Investors to Contact the Firm Before September 22nd
Sep 17, 2025 22:00
REPL INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Replimune Group, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Sep 17, 2025 16:00